Skip to main content

Table 2 Serum 25 (OH)D (ng/mL) levels at baseline and at 26 weeks

From: Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand

25(OH)D (ng/mL)

Observation Period

Group I (N = 28)

Group II (N = 64)

Group III (N = 94)

Total (N = 186)

≥ 50.0, n (%)

Baseline

1 (3.6)

2 (3.1)

1 (1.1)

4 (2.2)

26 weeks

1 (3.6)

3 (4.7)

1 (1.1)

5 (2.7)

30.0–49.9, n (%)

Baseline

10 (35.7)

21 (32.8)

26 (27.7)

57 (30.6)

26 weeks

15 (53.6)

47 (73.4)

55 (58.5)

117 (62.9)

20.0–29.9, n (%)

Baseline

14 (50.0)

36 (56.3)

52 (55.3)

102 (54.8)

26 weeks

12 (42.9)

14 (21.9)

36 (38.3)

62 (33.4)

<  20, n (%)

Baseline

3 (10.7)

5 (7.8)

15 (16.0)

23 (12.4)

26 weeks

0 (0)

0 (0)

2 (2.1)

2 (1.1)

Mean (SD)

Baseline

29.7 (8.8)

29.1 (8.4)

26.4 (10.0)

27.8 (9.4)

 

26 weeks

33.6 (7.9)

35.3 (7.4)

32.4 (6.8)

33.6 (7.3)

Min, Max

Baseline

16.8, 56.1

14.2, 58.0

8.9, 102.2

8.9, 102.2

26 weeks

22.7, 50.6

21.9, 58.1

17.2, 64.3

17.2, 64.3

p valuea

 

0.0913

< 0.0001

<  0.0001

< 0.0001

  1. Group I: Recent/current bisphosphonate-, strontium-, estrogen-, or SERM-treated patients; Group II: Patients being treated with other drugs; Group III: Treatment-naïve patients; aSerum 25(OH)D levels at week 26 compared with baseline. 25(OH)D 25-hydroxyvitamin D, SERM selective receptor estrogen modulator